A Study of FZ-AD005 in Patients With Advanced Solid Tumors

A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.

Trial Details

NCT ID
NCT06424665
Phase
PHASE1
Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • FZ-AD005
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Patients able to give written informed consent;
  • Age ≥ 18 and ≤ 75 years old, male or female;
  • Patients have histological or cytological diagnosis with advanced solid tumors ( especially SCLC or LCNEC);
  • Willingness to provide tumor tissue for testing ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →